Search and analyze individual stocks with comprehensive metrics
Senores Pharmaceuticals Limited
Fundamental Score
Senores Pharmaceuticals Limited Share Price & Market Analysis
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of SENORES across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (83.88%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (71.65%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 55.24x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
📊 Educational Market Overview
Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Senores Pharmaceuticals Limited
About SENORES
Company Details
Market Information
Performance
SENORES Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of SENORES?
SENORES is currently trading at ₹703.10 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of SENORES shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.
What is the P/E ratio of SENORES and what does it mean?
SENORES has a P/E ratio of 55.24x compared to the industry average of 33.97x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹55 for every ₹1 of annual earnings. This is higher than the industry average, suggesting either growth premium or potential overvaluation.
How is SENORES performing according to Bull Run's analysis?
SENORES has a Bull Run fundamental score of 37.7/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: 11.82%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.
What sector and industry does SENORES belong to?
SENORES operates in the Pharmaceuticals & Biotechnology industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Senores Pharmaceuticals Limited. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.
What is Return on Equity (ROE) and why is it important for SENORES?
SENORES has an ROE of 11.82%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently Senores Pharmaceuticals Limited generates profits from shareholders' equity. An ROE of 12% means the company generates ₹12 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.
How is SENORES's debt-to-equity ratio and what does it indicate?
SENORES has a debt-to-equity ratio of 0.40, which indicates moderate leverage that should be monitored. This means the company has ₹40 of debt for every ₹100 of equity. This conservative approach provides financial stability but may limit growth potential.
What is SENORES's dividend yield and is it a good dividend stock?
SENORES offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.
How has SENORES grown over the past 5 years?
SENORES has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%. These growth metrics show the company's ability to expand its business and improve profitability over time. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.
What is the promoter holding in SENORES and why does it matter?
Promoters hold 45.78% of SENORES shares, with 0.00% of promoter shares pledged. This promoter holding level suggests balanced ownership between management and public shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: 0.01%.
How does SENORES compare with its industry peers?
SENORES trades at P/E 55.24x vs industry average 33.97x, with ROE of 11.82% and ROCE of 11.40%. The stock trades at a premium to industry average, which may be justified by superior fundamentals. Peer comparison helps identify whether SENORES is outperforming its competitive set in profitability, growth, and valuation metrics.
What is SENORES's market capitalization and what category does it fall into?
SENORES has a market capitalization of ₹3235 crores, making it a Large-cap stock. Large-cap stocks offer stability and liquidity but typically slower growth. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.
What are the key financial ratios to consider for SENORES?
Key ratios for SENORES: ROE 11.82% (Good), ROCE 11.40%, P/E 55.24x, Debt-to-Equity 0.40, Interest Coverage 4.27x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.
How volatile is SENORES stock and what is its beta?
SENORES has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.
What is the 52-week high and low for SENORES?
SENORES has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹703.10, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.
What are the key risks associated with investing in SENORES?
Key risks for SENORES include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 0.40), and operational challenges. The stock has a Fundamental Score of 37.7/100, indicating higher risk requiring thorough due diligence. Sector-specific risks in Pharmaceuticals & Biotechnology include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.
What is SENORES's operating profit margin and how has it trended?
SENORES has a 5-year average Operating Profit Margin (OPM) of N/A%, which suggests room for improvement in operational efficiency. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. Monitor margin trends to assess management's ability to control costs and improve efficiency. Compare with industry peers to understand relative performance.
How is SENORES's quarterly performance in terms of sales and profit growth?
SENORES's recent quarterly performance shows YoY Sales Growth of 71.65% and YoY Profit Growth of 83.88%. This strong double-digit growth indicates excellent business momentum and management execution. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.
What is the FII and DII holding pattern in SENORES?
SENORES has FII holding of 3.66% and DII holding of 9.51%, totaling 13.17% institutional ownership. This institutional participation level shows the confidence of professional money managers. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.